News
OCUL
4.290
+0.94%
0.040
JMP Securities Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
TipRanks · 5d ago
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $12
Benzinga · 01/09 13:12
JMP Securities Adjusts Price Target on Ocular Therapeutix's to $12 From $25, Maintains Market Outperform Rating
JMP Securities Adjusts Price Target on Ocular Therapeutix's to $12 From $25, Maintains Market Outperform Rating
MT Newswires · 01/09 08:59
JMP Securities Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
TipRanks · 01/09 05:35
Ocular Therapeutix Sees 11% Rise in Q4 Dextenza Sales; Shares Rise
Ocular Therapeutix Sees 11% Rise in Q4 Dextenza Sales; Shares Rise
MT Newswires · 01/06 13:56
Ocular Therapeutix Provides 2022 Year End Corporate Update And Reviews Expected 2023 Milestones
Benzinga · 01/06 13:08
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US
MT Newswires · 12/12/2022 07:15
These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts
Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...
Simply Wall St. · 11/13/2022 12:10
Ocular Therapeutix And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 11/10/2022 10:41
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Benzinga · 11/09/2022 10:08
Ocular Therapeutix hits 52-week low after slashing revenue guidance
Seekingalpha · 11/08/2022 18:13
Ocular falls 12% as eye therapy Dextenza Q3 sales decline, cuts FY22 outlook
Seekingalpha · 11/08/2022 17:56
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/08/2022 17:51
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
Benzinga · 11/08/2022 16:30
Ocular Therapeutix Q3 Loss Widens, Revenue Drops; Shares Fall Sharply Tuesday
Ocular Therapeutix Q3 Loss Widens, Revenue Drops; Shares Fall Sharply Tuesday
MT Newswires · 11/08/2022 14:19
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BEDFORD, Mass., November 08, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it wi...
Business Wire · 11/08/2022 13:00
--Raymond James Adjusts Price Target on Ocular Therapeutix to $14 From $29, Maintains Strong Buy Rating
--Raymond James Adjusts Price Target on Ocular Therapeutix to $14 From $29, Maintains Strong Buy Rating
MT Newswires · 11/08/2022 11:58
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $9
Benzinga · 11/08/2022 11:30
Raymond James Maintains Strong Buy on Ocular Therapeutix, Lowers Price Target to $14
Benzinga · 11/08/2022 11:26
--HC Wainwright Trims Price Target on Ocular Therapeutix to $9 From $10, Maintains Buy Rating
--HC Wainwright Trims Price Target on Ocular Therapeutix to $9 From $10, Maintains Buy Rating
MT Newswires · 11/08/2022 11:06
More
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocularitching associated with allergic conjunctivitis. Its earlier stage development assets include axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet AMD and other retinal diseases. Its travoprost intracameral implant (OTX-TIC) is under Phase II clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. It has also completed Phase II clinical trials for cyclosporine intracanalicular insert (OTX-CSI) for the chronic treatment of dry eye disease and dexamethasone intracanalicular insert (OTX-DED) for the short-term treatment of the signs and symptoms of dry eye disease.